Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 7/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5095031 | 0.93 | HTR6 (0.47) | RXFP1KMT2AHTR6HTR1ADRD2 | |
| SCHEMBL4555077 | 0.83 | RXFP1 (0.50) | RXFP1KMT2APKMPOLBGAA | |
| SCHEMBL4555745 | 0.83 | RXFP1 (0.51) | RXFP1KMT2APKMHTR6POLB | |
| SCHEMBL5103835 | 0.82 | HTR6 (0.59) | RXFP1KMT2AHTR6HTR1ADRD2 | |
| SCHEMBL5095041 | 0.82 | HTR6 (0.52) | KMT2APKMHTR6HTR1ADRD2 | |
| SCHEMBL5097149 | 0.81 | RXFP1 (0.50) | RXFP1KMT2APKMHTR6POLB | |
| SCHEMBL5103856 | 0.80 | HTR6 (0.44) | KMT2AHTR6POLBHTR1ADRD2 | |
| SCHEMBL3672099 | 0.80 | HTR6 (0.61) | RXFP1KMT2APKMHTR6POLB | |
| SCHEMBL5213064 | 0.79 | NR3C2 (0.62) | RXFP1KMT2AHTR1ADRD2NR3C2 | |
| SCHEMBL4555130 | 0.78 | RXFP1 (0.51) | RXFP1KMT2APKMPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | claimed |
| EP-2121603-A2 | 6' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008101247-A2 | 6 ' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008101247-A2 | 6 ' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR1B, HTR1A | RXFP1 268/4885KMT2A 2980/4885PKM 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.